Business
Sierra Oncology expands SRA737 development program
Sierra Oncology expands SRA737 development program.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 1099G Sareum Holdings PLC 27 February 2018 \n\n\n\n\n\n (AIM: SAR)\n\n\n27 February 2018\n\n\n\n\nSAREUM HOLDINGS PLC\n \n(\"Sareum\" or \"the Company\")\n \nSareum notes that Sierra Oncology has significantly expanded its clinical development programme for SRA737 \n \n· Ongoing SRA737 clinical studies expanded to target aggregate enrolment of 200 patients across ten cancer indications\n· Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer\n \nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, announced that it has significantly expanded its clinical development programme for SRA737. Sierra Oncology issued an announcement today at 07:00 ET ahead of its Program Update event today at which it will provide an update on the progress of its portfolio of assets, with specific reference to its clinical development programme for SRA737. The Sierra management team will be joined by Dr Udai Banerji, Chief Investigator for its ongoing SRA737 Phase 1/2 clinical trials, and Dr Alan D'Andrea, a member of Sierra's DDR Advisory Committee. The event will take place at 10:00 am ET in New York and a live webcast will be available at www.sierraoncology.com. \n \nSierra Oncology announced noteworthy progress in the Dose Escalation Phase 1 portions for both of its ongoing Phase 1/2 clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737. Sierra announced expansion of the efficacy-oriented Phase 2 portions of both trials, which will now target aggregate enrolment of approximately 200 patients across ten cancer indications. Sierra also announced it is planning to initiate a Phase 1b/2 clinical trial in the fourth quarter of 2018 that will evaluate SRA737 in combination with ZEJULA® (niraparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The full announcement can be found at www.sierraoncology.com. \n \nSRA737-01 Phase 1/2 Monotherapy Trial: Trial Update and Expansion Plans \n \nThis trial consists of two phases, a safety-oriented Dose Escalation Phase 1 in unselected 'all-comer' patients and an efficacy-oriented Cohort Expansion Phase 2 i...